| 注册
首页|期刊导航|中国临床药理学杂志|德谷门冬双胰岛素联合二甲双胍治疗T2DM患者胰岛素抵抗的临床研究

德谷门冬双胰岛素联合二甲双胍治疗T2DM患者胰岛素抵抗的临床研究

郑振 杨宁宁 范学明

中国临床药理学杂志2025,Vol.41Issue(3):311-315,5.
中国临床药理学杂志2025,Vol.41Issue(3):311-315,5.DOI:10.13699/j.cnki.1001-6821.2025.03.003

德谷门冬双胰岛素联合二甲双胍治疗T2DM患者胰岛素抵抗的临床研究

Clinical trial of insulin degludec/insulin aspart combined with metformin in the treatment of insulin resistance in T2DM patients

郑振 1杨宁宁 1范学明1

作者信息

  • 1. 安徽医科大学附属六安医院内分泌科,安徽六安 237000
  • 折叠

摘要

Abstract

Objective To analyze the effect of insulin degludec/insulin aspart injection combined with metformin extended-release tablets on insulin resistance in patients with type 2 diabetes mellitus(T2DM).Methods T2DM patients were divided into control group and treatment group using a cohort method.The control group received oral metformin extended-release tablets(0.5 g,tid)and subcutaneous injections of insulin glargine injection(10 U,qd),while the treatment group received oral metformin extended-release tablets(0.5 g,tid)and subcutaneous injections of insulin degludec/insulin aspart injection(0.1-0.2 U·kg-1·d-1,evenly divided before breakfast and dinner).Both groups were treated for 12 weeks.The efficacy,blood glucose control[fasting blood glucose,2-hour postprandial blood glucose,glycated hemoglobin A1c(Hb A1c)],insulin function[fasting insulin(FINS),homeostasis model assessment of insulin resistance(HOMA-IR)and homeostasis model assessment-β(HOMA-β)]were compared,and safety was evaluated.Results A total of 49 cases were enrolled in the treatment group and 51 cases in the control group.The overall effective rates in the treatment and control groups were 93.88%(46 cases/49 cases)and 80.39%(41 cases/51 cases),respectively,showing a statistically significant difference(P<0.05).After treatment,the fasting blood glucose levels in the treatment and control groups were(5.83±0.79)and(6.53±0.81)mmol·L-1;the 2-hour postprandial blood glucose levels were(7.73±0.86)and(8.41±0.97)mmol·L-1;HbAlc levels were(6.34±0.88)%and(6.80±0.92)%;FINS levels were(6.02±1.13)and(7.13±1.04)mU·L-1;HOMA-IR values were 1.56±0.20 and 2.07±0.23;HOMA-βvalues were 51.67±3.18 and 47.06±3.31,respectively,with all differences being statistically significant(all P<0.05).The adverse drug reactions in the treatment group mainly included hypoglycemia,nausea,dizziness,and diarrhea,while the adverse drug reactions in the control group mainly included hypoglycemia and nausea.The incidence of adverse drug reactions was 10.20%(5 cases/49 cases)in the treatment group and 11.76%(6 cases/51 cases)in the control group,with no statistically significant difference(P<0.05).Conclusion The combination of insulin degludec/insulin aspart injection and metformin extended-release tablets can improve insulin resistance and regulate blood glucose levels in T2DM patients,with good safety profiles.

关键词

德谷门冬双胰岛素注射液/二甲双胍缓释片/2型糖尿病/血糖/胰岛素抵抗

Key words

insulin degludec/insulin aspart injection/metformin extended-release tablet/type 2 diabetes mellitus/blood glucose/insulin resistance

分类

医药卫生

引用本文复制引用

郑振,杨宁宁,范学明..德谷门冬双胰岛素联合二甲双胍治疗T2DM患者胰岛素抵抗的临床研究[J].中国临床药理学杂志,2025,41(3):311-315,5.

中国临床药理学杂志

OA北大核心

1001-6821

访问量4
|
下载量0
段落导航相关论文